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Abstract. Blockade of the programmed-death 1 receptor 
(PD-1)/programmed-death ligand (PD-L1) pathway efficiently 
reduces tumour growth and improves survival. Durable 
tumour regression with blockade of the PD-1/PD-L1 check-
point has been demonstrated in recent clinical studies. Oral 
squamous cell carcinoma (OSCC) is highly immunosuppres-
sive, and PD-L1 expression has been proposed as a potential 
mechanism responsible for this phenotype. Despite the fact 
that anti-PD-1 treatment can produce durable responses, such 
therapy appears to benefit only a subset of patients. Thus, it is 
important to understand the mechanisms underlying regula-
tion of PD-L1 expression in the OSCC microenvironment. In 
this study, we showed that PD-L1 expression in high-grade 
invasive OSCC cell lines was lower than that in a low-grade 
invasive OSCC line and found a close correlation between 
PD-L1 expression and the epithelial-mesenchymal transition 
(EMT). PD-L1 expression was upregulated in macrophages 
and dendritic cells (DCs) in high-grade invasive human OSCC 
tissues or co-cultured with mesenchymal-phenotype OSCC 
cells in vitro. TLR4-inhibitory peptide successfully suppressed 
PD-L1 upregulation on macrophages and DCs co-cultured 
with mesenchymal-phenotype OSCC cells, suggesting that 
some EMT-induced tumour antigen is critical for PD-L1 
induction on tumour-associated macrophages and DCs. 
Further studies are necessary to explore the impact of EMT on 
the tumour immune microenvironment and to identify poten-
tial biomarkers for selecting patients who might preferentially 
benefit from PD-1/PD-L1 blockade or immunotherapies more 
broadly.
Introduction
The programmed-death 1 receptor (PD-1, CD279)/
programmed-death ligand 1 (PD-L1, B7-H1, CD274) pathway 
has emerged as a critical inhibitory pathway that regulates 
T cell responses and maintains immune suppression (1-4). 
Oral squamous cell carcinoma (OSCC) is a malignant tumour 
found most often in the head and neck region (5,6) that is highly 
immunosuppressive in general, and PD-L1 expression has been 
proposed as a potential mechanism facilitating this phenotype 
(7-9). PD-L1 is expressed in many tumours in a constitutive 
and interferon-γ (IFN-γ)-inducible manner. PD-L1 binds to an 
inhibitory receptor (PD-1), which is a member of the B7 family 
of receptors (4), and to the costimulatory molecule CD80 
(B7-1) (10). PD-1 is expressed on activated T cells, and liga-
tion of PD-1 by tumour-associated PD-L1 induces apoptosis 
or downregulation of effector cytotoxic T lymphocytes (CTL), 
resulting in an escape from T-cell mediated immune surveil-
lance (11). Blockade of the PD-L1/PD-1 pathway efficiently 
reduces tumour growth and improves survival (7,12-15). 
Durable tumour regression with blockade of the PD-1/PD-L1 
checkpoint has been demonstrated in recent clinical studies 
(1,2), leading to the recent registration of an anti-PD-1 anti-
body for advanced melanoma and non-small cell lung cancer. 
In addition, the clinical efficacy of an anti-PD-1 monoclonal 
antibody in OSCC has been observed in phase I studies (16). 
In general, the response to PD-1 blockade has been commonly 
correlated with PD-L1 expression in treated tumours (1).
Although anti-PD-1 treatment can produce durable 
responses, it appears to benefit only a subset of patients. Chen 
et al recently demonstrated a molecular link between the 
epithelial-mesenchymal transition (EMT) and intratumoural 
CD8+ T cell suppression through PD-L1 regulation, in both 
animal models and human cell lines (17). EMT is a key 
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process that drives cancer metastasis and drug resistance, and 
has been associated with poor prognosis in multiple cancers, 
including OSCC (18-20). For instance, positive staining for 
the mesenchymal marker vimentin occurs in specimens from 
non-small cell lung cancer (NSCLC) patients who develop 
resistance to epidermal growth factor receptor (EGFR) inhibi-
tors, suggesting that EMT has been triggered in such tumours 
(21-23). Previously, we found that loss of EGFR expression in 
OSCC was associated with EMT and might have functional 
implications in the resistance to cetuximab treatment (24). 
However, the impact of EMT on reprogramming the tumour 
immune microenvironment is largely unknown.
To predict the efficacy and optimize anti-PD-1 therapy, 
alone or in combination, it is important to understand the 
mechanisms controlling PD-L1 expression. In this study, we 
focused on the regulation of PD-L1 expression in OSCC, 
and the mechanism of regulation of PD-L1 expression in the 
tumour microenvironment.
Materials and methods
Cell culture. Three human OSCC cell lines established from 
tumour biopsies with different grades of invasive abilities 
were used, including OSC-20 cells (low-grade invasive cells), 
OSC-19 cells (low-grade invasive cells), and TSU cells (high-
grade invasive cells). The OSC-20 cell line was derived from a 
58-year-old female with tongue cancer metastatic to the cervical 
lymph nodes (25). OSC-19 was derived from a 61-year-old male 
with tongue cancer metastatic to the cervical lymph nodes (26). 
The TSU cell line was established from a patient with gingival 
squamous cell carcinoma who had developed marked leuko-
cytosis (27). In addition, normal human gingival fibroblasts 
(HGFs; ATCC no. CRL-2014) obtained from the American 
Type Culture Collection (Manassas, vA, USA) served as a 
control. Macrophages and dendritic cells (DCs) were generated 
from human peripheral blood mononuclear cells (PBMCs), as 
described previously (28,29). PBMCs were obtained by vene-
puncture into an 8-ml vacutainer CPT Cell-Preparation Tube 
(BD Vacutainer Systems, Franklin Lakes, NJ, USA). Briefly, 
monocyte-derived macrophages were generated by incubating 
monocytes (1x106/ml) in RPMI-1640 medium containing 10% 
fetal bovine serum (FBS), 2 mM glutamine, 25 mM HEPES, 
100 U/ml penicillin, 100 µg/ml streptomycin, and 50 ng/ml 
GM-CSF (PeproTech, Rocky Hill, NJ, USA) at 37˚C in a CO2 
incubator for 7 days. Induced macrophages were examined 
using an anti-macrophage antibody (MAC387; Abcam, Tokyo, 
Japan). Monocyte-derived DCs were generated by incubating 
monocytes at 1x106 cells/ml in G4 medium (G4 Dendritic 
Cell Generation kit; Humanzyme, IL, USA) at 37˚C in a CO2 
(5%) incubator for 7 days. Induced DCs were examined using 
an anti-DC antibody (CD83; Abcam). Carcinoma-associated 
fibroblasts (CAFs) were generated by the addition of recom-
binant TGF-β1 to confluent growth-arrested cell monolayers, 
as previously described (30,31). Recombinant TGF-β1 (R&D 
Systems Europe Ltd., Abingdon, Uk; 50 ng/ml) was prepared 
in serum-free culture medium. CAFs were examined using 
anti-αSMA (R&D Systems Europe Ltd.) antibodies. Culture 
inserts (1-µm pore size) were purchased from Corning Japan 
(Tokyo, Japan). MyD88 homodimerization-inhibitor peptide 
and toll-like receptor 4 (TLR4)-inhibitory peptide were 
purchased from Imgenex (San Diego, CA, USA) and Novus 
Biologicals (Littleton, CO, USA), respectively, and used in the 
cell-blocking study.
Tissue samples. Experiments using human tissues were 
approved by the ethics committee of the kanazawa University 
Graduate School of Medical Science (IRB no. 2014-004, 
352-2), and written informed consent was obtained from 
patients providing tissue specimens. The subjects included 
24 patients with primary OSCC who underwent surgical 
resection at the Department of Oral and Maxillofacial 
Surgery at kanazawa University Hospital between 2000 and 
2008. The patients with carcinoma were aged from 43 to 89 
years (64.4±11.2 years, mean ± SD). The grade of tumour 
differentiation was determined according to the criteria 
proposed by the world Health Organization (32). The mode 
of tumour invasion was assessed according to the classifica-
tion by Yamamoto et al (33).
RNA extraction, cDNA synthesis, and quantitative real-time 
PCR (qPCR). The mRNA expression levels of PD-L1, PD-L2, 
E-cadherin, N-cadherin, vimentin, and Snail1 were analysed 
using a Rotor-Gene Q 2plex System (Qiagen, Hilden, Germany) 
with FAM/ZEN/IBFQ probes (Integrated DNA Technologies, 
Inc., Coralville, IA, USA; DNA sequences not opened). 
Total RNA was extracted using the RNeasy Protect Mini 
kit (Qiagen), and cDNA was obtained using the PrimeScript 
first-strand cDNA Synthesis kit (Takara, Tokyo, Japan). All 
reactions were performed according to the manufacturer's 
instructions. We amplified 18S rRNA as an internal standard 
using HEX/ZEN/IBFQ probes (Integrated DNA Technologies, 
Inc.; DNA sequences not opened). Relative expression levels 
were calculated using the ∆∆Ct method for qPCR (34), which 
presents the data as fold-differences in expression level rela-
tive to a calibrator sample; in this case, the mean expression of 
3 experimental measurements of 18S rRNA in control cells or 
vehicle-treated cells.
Western blot analysis. The cultured cells were lysed with 
Pierce RIPA buffer (Thermo Scientific, Waltham, MA, USA). 
Lysates mixed with sample buffer were electrophoretically 
separated and transferred onto membranes. Membranes were 
blocked with Blocking One (Nacalai Tesque, kyoto, Japan), 
followed by incubations with an anti-PD-L1, E-cadherin, 
N-cadherin, vimentin, or Snail1 antibody (Abcam) and an anti-
human β-actin antibody (Cell Signaling Technology, Tokyo, 
Japan). After washing with Tris-buffered saline (TBS) with 
0.05% Tween, membranes were incubated with a horseradish 
peroxidase-conjugated anti-mouse IgG. After washing with 
TBS-0.05% Tween, membranes were incubated with the ECL 
Prime western Blotting Detection reagent (GE Healthcare, 
Little Chalfont, Uk). Signals were detected and analysed 
using C-DiGit (M&S TechnoSystems, Tokyo, Japan).
EMT induction. OSC-20 cells were seeded at 70% confluence 
and cultured for 48 and 72 h in Dulbecco's modified Eagle's 
medium (Sigma-Aldrich Japan, Tokyo, Japan) with 0.5% FBS 
(Hyclone, Logan, UT, USA) to induce EMT. Recombinant 
human TGF-β1 (R&D Systems, Minneapolis, MN, USA) was 
added to a final concentration of 5 ng/ml.
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Immunohistochemistry. Each specimen was fixed in 10% 
buffered formalin and then embedded in paraffin to prepare 
serial sections. Immunohistochemical staining was performed 
using antibodies against PD-L1, Snail, vimentin, CD83, 
macrophages (MAC387), αSMA, and fibroblast activation 
protein (FAP) (Abcam). Primary antibodies were detected 
using Envision Single reagents (Dako Japan, Tokyo, Japan), 
Alexa Fluor 488-labeled goat anti-mouse IgG (Cell Signaling 
Technology), and Alexa Fluor 546-labeled goat anti-rabbit IgG 
(Thermo Fisher Scientific, Rockford, IL, USA). Staining speci-
ficity was confirmed using the Universal Negative Control for 
IS-Series Rabbit Primary Antibodies reagent (IS600; Dako 
Japan) as a negative control, instead of the matching primary 
antibody. After mounting with ProLong Gold Antifade reagent 
(Thermo Fisher Scientific, Tokyo, Japan), the tissues were 
subjected to fluorescence microscopy. Three regions were 
image-captured under a light microscope at x100 magni-
fication, and the images were evaluated based on number 
of stained tumour cells, following the method described by 
kimura et al (24). PD-L1 expression was evaluated based on 
the extent of immunolabelling in tumour cell membranes and 
was classified on a four-point scale: 0 (no labelling, or label-
ling in <10% of tumour cells); 1 (weak labelling, homogeneous 
or patchy, in >10% of tumour cells); 2 (moderate labelling, 
homogeneous or patchy, in >10% of tumour cells); 3 (intense 
labelling, homogeneous or patchy, in >10% of tumour cells). 
These scores were subsequently grouped into 2 categories: low 
expression (0 or 1) and high expression (2 or 3).
Statistical analysis. Statistical analyses were conducted using 
JMP 12.0 software (SAS Institute, Inc., Cary, NC, USA). 
The qPCR data are presented as the mean ± standard error 
of the mean (SEM). Differences between groups were tested 
for statistical significance using the 2-tailed Mann-Whitney 
U test. Differences were considered significant at P<0.05.
Results
PD-L1 and PD-L2 expression in 3 different grades of inva-
sive OSCC cell lines. PD-L1 and PD-L2 mRNA expression 
on 3 human OSCC lines with different grades of invasiveness 
(OSC-19, OSC-20, and TSU) were analysed. The qPCR data 
are presented as fold-differences relative to the mean values 
from 3 experiments with HGF cells (Fig. 1A). Among the 
3 OSCC cell lines, the PD-L1 mRNA expression level ranged 
from 5.73 to 20.48-fold higher than in HGF cells (Fig. 1A), 
while PD-L2 mRNA expression ranged from 0.38 to 1.48-fold 
higher than in HGF cells (Fig. 1A). In particular, the expres-
sion of PD-L1 mRNA in low-grade invasive cells (OSC-20 
cells) was highest among the 3 OSCC cell lines. Upregulation 
of PD-L1 mRNA in high-grade invasive cells (TSU cells) was 
not as remarkable compared to that in the other 2 low-grade 
invasive cells (OSC-20 and OSC-19 cells). PD-L2 expression 
on the 3 different invasive human OSCC lines was much 
lower, and differences were negligible compared to that of 
PD-L1. we further analysed PD-L1 expression at the protein 
level. Both low-grade invasive cells (OSC-20 and OSC-19) 
had a PD-L1 protein expression level higher than that of TSU 
cells. HGF cells exhibited negligible PD-L1 protein expression 
(Fig. 1B).
The relationship between EMT and PD-L1 expression in 
human OSCC cell lines. To evaluate whether PD-L1 expression 
is associated with EMT features, we analysed the mRNA- and 
protein-expression levels of E-cadherin, N-cadherin, vimentin, 
and Snail1 in the human OSC-19, OSC-20, and TSU lines with 
different degrees of invasiveness. The mRNA expression levels 
of these EMT-associated genes in OSC-19 and TSU cells are 
presented as fold-differences relative to those in OSC-20 cells. 
TSU cells displayed a mesenchymal phenotype manifested 
by the loss of E-cadherin and acquisition of N-cadherin, 
vimentin, and Snail compared to the corresponding expression 
levels in OSC-20 and OSC-19 cells (Fig. 2A and B). OSC-20 
cells (epithelial phenotype) were exposed to TGF-β1 to deter-
mine whether such exposure could change the mRNA- and 
protein-expression levels of EMT-associated genes and PD-L1 
(Fig. 2C and D). The mRNA-expression levels are presented 
as fold-differences relative to that of vehicle control-treated 
Figure 1. PD-L1 and PD-L2 expression on 3 OSCC cell lines with different 
grades of invasiveness. (A) Relative mRNA-expression levels of PD-L1 
and PD-L2 in the OSC-20, OSC-19, TSU, and HGF cell lines. Expression 
levels are displayed as fold-differences relative to control cells (HGF cells). 
(B) Expression of the PD-L1 protein in OSC-20, OSC-19, TSU, and HGF 
cells was assessed by immunoblot analysis. The arrow indicates PD-L1. 
β-actin was detected as a loading control.
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cells. Serial examination of EMT markers (loss of E-cadherin 
and upregulation of N-cadherin, vimentin, and Snail) at 
48 and 72 h showed that TGF-β1 treatment resulted in EMT 
in OSC-20 cells (Fig. 2C). We further confirmed E-cadherin 
downregulation and N-cadherin, vimentin, and Snail upregu-
lation at the protein level at 72 h after TGF-β1 treatment 
(Fig. 2D). Strikingly, the total PD-L1 mRNA and protein 
levels were reduced in OSC-20 cells after EMT induction by 
TGF-β1 treatment.
Immunohistochemical analysis of human OSCC tissues. To 
confirm downregulation of PD-L1 on high-grade invasive cells 
compared to low-grade invasive cells, we further studied immu-
nohistochemical analysis using 3-, 4C-, and 4D-grade invasive 
OSCC tissues. Previously, we demonstrated that OSC-20 and 
OSC-19 cells implanted into nude mice successfully repro-
duced the same types of diffuse invasive tumours (grades 3 
and 4C in terms of the mode of invasion, respectively) (35), 
and repeated inoculation with TSU cells successfully repro-
duced the formation of grade 4D OSCC tumours in nude mice 
(36). with the low-grade invasive OSCC lines (grades 3 and 
4C, mode of invasion), immunohistochemical analysis demon-
strated that PD-L1 was detected in cancer cells, but not in 
stromal cells (Fig. 3A). However, PD-L1 signals were detected 
in stromal cells of high-grade invasive OSCC (grade 4D, mode 
of invasion), whereas PD-L1 was not detected in the cancer 
cells (Fig. 3A). Table I displays the correlations between 
PD-L1 expression and the clinicopathological factors. PD-L1 
expression in high-grade invasive OSCCs (4D, mode of inva-
sion) was significantly downregulated compared to low-grade 
invasive OSCCs (3 and 4C, mode of invasion) (P=0.0392). 
In contrast, PD-L1 expression did not correlate with tumour 
size (P=0.873), lymph node metastasis (P=0.542), local recur-
rence (P=0.083), or histological differentiation (P=0.145). 
Immunohistochemical analysis demonstrated that signals of 
EMT-related protein (vimentin and Snail1) were detected in 
cancer cells in human OSCC tissues classified as grade 4D in 
terms of the mode of invasion (Fig. 3B). To analyse which cells 
expressed PD-L1 in the cancer stroma, we investigated cells 
surrounding the cancer cells by studying several biomarkers. 
Immunofluorescence analysis demonstrated that most CD83 
(DC marker)-positive cells expressed PD-L1 and a fraction 
of MAC387 (macrophage marker)-positive cells expressed 
the PD-L1 protein in high-grade invasive OSCC tissues 
(grade 4D, mode of invasion; Fig. 3C). However, αSMA or 
FAP (CAF marker)-positive cells did not co-localize with 
PD-L1 expressing cells (Fig. 3C).
PD-L1 expression in macrophages or DCs co-cultured with 
high-grade, invasive OSCC cells. The above immunohisto-
chemical analysis demonstrated that macrophages and DCs 
expressed PD-L1 in stromal cells in high-grade invasive OSCC 
tissues. Thus, we performed further in vitro studies to confirm 
PD-L1 expression in macrophages and DCs in vitro. we found 
Figure 2. Relationship between EMT and PD-L1 expression on human OSCC cell lines. (A) Relative mRNA expression levels of the EMT-associated genes 
E-cadherin, N-cadherin, vimentin, and Snail, in OSC-20, OSC-19, and TSU cell lines. Expression differences in OSC-19 and TSU cells are displayed as fold-
changes relative to the expression levels in OSC-20 cells. (B) Expression of the EMT-associated protein in OSC-20, OSC-19, and TSU cells was assessed by 
immunoblot analysis. β-actin was detected as a loading control. (C) Relative mRNA expression levels of PD-L1 and the EMT-associated genes E-cadherin, 
N-cadherin, vimentin, and Snail in TGF-β-treated OSC-20 cells. OSC-20 cells were treated with human TGF-β or a vehicle control for 48 and 72 h. Expression 
differences are displayed as fold-changes relative to the control vehicle at 48 and 72 h. (D) Expression of the EMT-associated protein in TGF-β-treated OSC-20, 
OSC-19, and TSU cells was assessed by immunoblot analysis. β-actin was detected as a loading control.
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Figure 3. Immunohistochemical analysis of human OSCC tissues. (A) Localization of PD-L1 in OSCC tissues (mode of invasion: grade 3, 4C or 4D). Positive 
staining of cancer cells (arrow) or stroma cells (arrowhead). (B) Localization of vimentin or snail in OSCC tissues (mode of invasion: grade 4D). Positive 
staining of cancer cells (arrow). (C) Fluorescent images of MAC387 (green), CD83 (green), αSMA (green), FAP (green), PD-L1 (red), and DAPI (blue) in 
OSCC tissues (mode of invasion: grade 4D). Double-positive staining of cells (arrowhead). Scale bar, 100 µm.
Figure 4. PD-L1 expression on macrophages or DCs co-cultured with high-grade invasive OSCC cells. (A) Expression of PD-L1 mRNA in macrophages or 
DCs or CAFs co-cultured with TSU or OSC-20 cells. Expression levels are displayed as fold-differences relative to the corresponding mRNA levels in control 
TSU or OSC-20 cells. The data shown represent the mean ± SEM. *P<0.05. (B) Immunohistochemical analysis of macrophages or DCs co-cultured with TSU 
cells, or macrophages, DCs, and TSU cells cultured separately. Positive immunostaining of macrophages or DCs (arrow) and a lack of staining of TSU cells 
(arrowhead). Scale bar, 50 µm. (C) Expression of PD-L1 mRNA in macrophages or DCs after adding the supernatant from a TSU cell culture or TSU cells in a 
culture insert. Expression levels are displayed as fold-differences relative to the corresponding mRNA levels in control TSU cells. The data shown represent the 
mean ± SEM. *P<0.05. (D) PD-L1 upregulation on macrophages or DCs co-cultured with TSU cells was suppressed by a MyD88 homodimerization-inhibitor 
peptide or TLR4-inhibitory peptide, but not by a control peptide (CP). Expression levels are displayed as fold-differences relative to the corresponding levels 
observed in control TSU cells. The data shown represent the mean ± SEM. *P<0.05.
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that PD-L1 expression increased significantly (~10-fold) in 
macrophages or DCs co-cultured with TSU cells, relative to 
that observed in TSU cells, macrophages or DCs cultured 
separately. Differences in PD-L1 expression were negligible 
between TSU cells co-cultured with CAFs and TSU cells or 
CAFs cultured separately (Fig. 4A). In addition, PD-L1 expres-
sion in macrophages or DCs co-cultured with OSC-20 cells, as 
well as in separate cultures of OSC-20 cells and macrophages 
or DCs, did not change (Fig. 4A). Differences in PD-L1 expres-
sion were negligible between OSC-20 cells co-cultured with 
CAFs and OSC-20 cells or CAFs cultured separately (Fig. 4A).
Next, macrophages or DCs co-cultured with TSU cells 
were immunostained using an anti-PD-L1 antibody to deter-
mine which cell type expressed PD-L1. PD-L1 signals were 
detected in macrophages or DCs, but not TSU cells (Fig. 4B). 
In particular, macrophages or DCs attached to TSU cells that 
expressed PD-L1. PD-L1 was not detected in the separate 
cultures of TSU cells, macrophages, or DCs (Fig. 4B). PD-L1 
upregulation was not observed after adding the supernatant 
from a TSU cell culture to macrophages or DCs (Fig. 4C). 
PD-L1 upregulation was inhibited after adding TSU cells in 
culture inserts to macrophages or DCs (Fig. 4C). Further, we 
used a blocking peptide to study the mechanism of toll-like 
receptors in PD-L1 induction in macrophages or DCs 
co-cultured with TSU cells. PD-L1 upregulation in macro-
phages or DCs co-cultured with TSU cells was significantly 
suppressed by treatment with the MyD88 homodimerization-
inhibitor peptide or TLR4-inhibitory peptide (Fig. 4D).
Discussion
PD-L1 is a ligand of the inhibitory receptor PD-1, and the 
PD-L1/PD-1 pathway is involved in the induction and mainte-
nance of peripheral immunotolerance in cancer tissues (11,37). 
Previous data demonstrated that constitutive expression of 
PD-L1 occurs in various human cancers, including squamous 
cell carcinomas of the lung, esophagus, and head and neck; 
other types of carcinomas of the colon, ovaries, bladder, 
and breast; melanoma; and glioma (7,12,13,37-45). Tumour-
associated PD-L1 is closely correlated with a poor prognosis 
and/or higher malignancy grade. In general, PD-1 blockade has 
been commonly correlated with PD-L1 expression in treated 
tumours (1). Here, we demonstrated that PD-L1 expression in 
3 OSCC cell lines was significantly upregulated compared to 
that in normal cells; thus, PD-L1 may play a greater role in 
immunotolerance in the cancer microenvironment than PD-L2 
does. However, it was surprising that PD-L1 expression in 
high-grade invasive OSCC cell lines was lower than that in a 
low-grade invasive OSCC line because these data contradicted 
previous findings with other tumour types (7,12,13,37-45). 
while the molecular mechanisms that account for this differ-
ence remain to be determined, we suggest that they may be 
confined to cancer subtypes with a unique molecular profile. 
Clearly, further investigation will be required to test this 
hypothesis.
Previously, we demonstrated that high-grade invasive 
OSCC cells have a mesenchymal phenotype (24). In this study, 
we confirmed the EMT-associated genes were upregulated in 
high-grade invasive OSCC tumour cells (TSU). Interestingly, 
PD-L1 expression in TSU OSCC cells (with a mesenchymal 
phenotype) was downregulated compared to that in OSC-19 
and OSC-20 cells (with an epithelial phenotype). we also 
demonstrated that TGF-β1 caused OSC-20 cells (with an 
epithelial phenotype) to undergo an EMT-associated gene 
switch, resulting in lost PD-L1 expression. These results 
indicated that a close correlation existed between PD-L1 
expression and EMT, and that the net effect of TGF-β1 
signalling was PD-L1 downregulation with a concomitant 
EMT-associated gene switch in tumour cells. However, further 
studies are needed to explain why OSCC maintains high-grade 
invasive ability even after PD-L1 downregulation in cancer 
cells. Our above data were developed in cell line models, 
which do not reflect contributions of the tumour microenvi-
ronment and immune responses, which play important roles in 
therapeutic responses. Further studies of the precise molecular 
mechanisms underlying the association between EMT and the 
regulation of PD-L1 expression in a human tumour microenvi-
ronment should be conducted.
By analysing the immunomarkers PD-L1, vimentin, and 
snail1, we confirmed the loss of PD-L1 expression and the 
mesenchymal phenotype of cancer cells in high-grade invasive 
human OSCC tissues (grade 4D). Interestingly, strong PD-L1 
signals were detected in stromal cells of high-grade invasive 
human OSCC tissues (grade 4D), rather than in cancer cells. 
In low-grade invasive human OSCC tissues (grade 3 and 4C), 
PD-L1 expression was seen only in cancer cells, but not in 
Table I. Correlation between PD-L1 expression and the OSCC 
clinicopathological factors of the patients.
 PD-L1 expression -----------------------------------------------------
Factor High (n=13) Low (n=11) P-value
T category
 T1   4 3 0.873
 T2   7 5
 T3    0 1
 T4   2 2
N category
 Negative 12 7 0.542
 Positive   1 4
Local reccurence
 Negative 10 5 0.083
 Positive 3 6
Differentiation
 well 9 7 0.145
 Moderately 3 1
 Poorly 1 3
Mode of invasion
 Grade 3 6 2 0.0392a
 Grade 4C 5 3
 Grade 4D 2 6
aP<0.05.
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stromal cells. These data suggested that invasiveness and the 
EMT signature were inversely correlated with PD-L1 expression 
in cancer cells and directly correlated with PD-L1 expression 
in stromal cells. Potentially, some interaction occurred between 
EMT-induced OSCC cells and stromal cells. A previous report 
provided evidence that PD-L1 is not only expressed by tumour 
cells, but also by tumour-associated macrophages, DCs, and 
CAFs (46,47). In this study, we detected a strong presence of 
PD-L1 in macrophages or DCs in cancer stroma tissues via 
immunofluorescence analysis. While the expression levels of 
PD-L1 in tumour cells, tumour-infiltrating immune cells have 
recently been shown to correlate with clinical responses to 
anti-PD-1 therapy (48-50). Only a subset of patients with PD-L1-
expressing tumours had clinical responses and other patients 
(without PD-L1 staining) demonstrated clinical benefits, indi-
cating that additional factors in the tumour microenvironment 
(such as stroma cell PD-L1 expression) may exist that define the 
subgroup of patients who derive benefit.
Here, we showed that macrophages or DCs co-localized 
with PD-L1 protein expression in cancer stromal tissues by 
immunofluorescence staining. We performed further in vitro 
analysis of the effects of direct interactions between cancer 
cells and macrophages or DCs on PD-L1 expression. we 
showed here that PD-L1 expression was upregulated in 
macrophages or DCs co-cultured with TSU cells, but upregu-
lation was not observed in CAFs co-cultured with TSU cells. 
Immunostaining of co-cultured macrophages or DCs and 
TSU cells revealed that PD-L1 upregulation was observed 
only in macrophages or DCs, but not in co-cultured TSU 
cells. Although the association between PD-L1 expression 
and macrophages or DCs reported here is suggestive of an 
adaptive resistance mechanism, it is still necessary to explain 
why PD-L1 was predominantly expressed by macrophages or 
DCs, rather than cancer cells. If cancer cell-derived IFN-γ is 
indeed a major mediator of PD-L1 expression in oral cancer, 
as described in other settings (51), then oral cancer cells may 
be less IFN-γ-responsive than macrophages or DCs. Another 
possibility is that IFN-γ is expressed at lower levels in TSU cells, 
as we showed here that the supernatant of cultured TSU cells 
or TSU cells in culture insert did not induce PD-L1 expression 
in macrophages or DCs. Alternatively, perhaps while cleaning 
up tumour debris, macrophages and DCs begin to present high 
levels of tumour antigens, making them prime targets for T cell 
recognition. In fact, in this study, a TLR4-inhibitory peptide 
successfully suppressed PD-L1 upregulation in macrophages 
or DCs co-cultured with TSU cells. In this scenario, PD-L1 
expression may provide a means for protecting macrophages or 
DCs against cell death, and tumour antigen could be induced 
by EMT, because PD-L1 upregulation was not observed in 
macrophages or DCs co-cultured with OSC-20 cells with an 
epithelial phenotype (Fig. 4A).
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